DeRoyal Industries, Inc.
http://www.deroyal.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DeRoyal Industries, Inc.
Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout
The acquisition of Mariana will complement Novartis’s lutetium-based radioligand therapies with candidates using actinium. Lilly, Bristol and AstraZeneca all have made recent high-priced buys in the space.
BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth
Revlimid and Eliquis beat expectations in the first quarter, but the products have dwindling exclusivity, making new drugs the main focus for Bristol. So the company will reinvest cost savings in R&D.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
Pharma On The Hunt For Oncology Partners Across Modalities
The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.
Company Information
- Industry
- Medical Devices
- Services
-
Services
- Managed Care, Insurance, Integrated Systems
- Outcomes Studies
- Services sold to health care facilities
- Specialized outpatient services
- Utilization Review, Claims Processing, Cost Contai
-
Managed Care, Insurance, Integrated Systems
- Specialized Provider Networks
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice